## INFORMATION DISCLOSURE O+S\*ATEMENT BY APPLICANT

	Application No.	10/568,488		
	Filing Date	February 14, 2006		
	First Named Inventor	Monia, Brett P.		
	Art Unit	1635		
	Examiner	Unknown Terra C. Gibbs		
	Attorney Docket No.	SPH-0859USA / ISIS.029NP		

(Multiple sheets used when necessary) JUN 0 7 2007 SHEET 1 OF 1

PADEMAR	<i>\$</i>	U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
	1	5801154	09-01-1998	Baracchini, et al.		

FOREIGN PATENT DOCUMENTS

Publication

## Foreign Patent Document Pages, Columns, Lines Cite Examiner Name of Patentee or T1 Country Code-Number-Kind Code Date Where Relevant Passages or Applicant Initials No. MM-DD-YYYY Relevant Figures Appear Example: JP 1234567 A1 NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials No. number(s), publisher, city and/or country where published. /TCG/ ESCOTT, K.G., etal., "Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat," British Journal of Pharmacology (2000) 131:173-176. TAUBE, et al., Inhibition of Early Airway Neutrophilia Does Not Affect Development of Airway /TCG/ Hyperresponsiveness, 2004, American Journal of Respiratory Cell and Molecular Biology, Vol. 30 pgs 837-843.

UNDERWOOD, et al., SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine

Production, Airways Eosinophil Infiltration, and Persistance, 2000, The Journal of Pharmacology and

3831803 060107

/TCG/

/Terra Cotta Gibbs/ Examiner Signature

Date Considered

09/12/2008

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Experimental Therapeutics, Vol 293, No. 1, pgs 281-288.